Analyst consensus rating
Zentalis Pharmaceuticals Analyst Rating: Buy
Direct answer
Zentalis Pharmaceuticals's consensus rating is Buy.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $6.89.
Forecast evidence checked September 9, 2026.
Get free Zentalis Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $4.03
- Average price target
- $6.89
- High price target
- $10.00
- Low price target
- $4.00
- Low target gap
- -0.7%
- Target upside
- +70.9%
- High target gap
- +148.1%
- Target range width
- 148.9%
- Consensus rating
- Buy
- Analysts
- 9
- Evidence date
- September 9, 2026
- Valid through
- September 16, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals has a verified Buy consensus. The same dataset has an average price target of $6.89.
How far are Zentalis Pharmaceuticals's low and high targets from the recorded price?
The low target implies -0.7%, while the high target implies +148.1%.
How many analysts are included in Zentalis Pharmaceuticals's consensus?
The verified consensus includes 9 analysts.
How is Zentalis Pharmaceuticals's target upside or downside calculated?
The average target of $6.89 is divided by the recorded price of $4.03, then one is subtracted to produce +70.9%. This does not guarantee a future return.
When was Zentalis Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-09-09. The dataset is valid through 2026-09-16.